Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation

Fexuprazan (DWP14012), a potassium-competitive acid blocker, is a medical formulation prescribed to inhibit the secretion of gastric acid. The present study encompasses a comparative evaluation of pharmacokinetic (PK) analysis between the previous (reference) and size-reduced (test) formulation of f...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, A-Young, Yoo, Hyounggyoon, Shin, Wonsuk, Lee, Yil-Seob, Lee, Hyejung, Kim, Sung-Eun, Kim, Anhye
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Clinical Pharmacology and Therapeutics 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079506/
https://www.ncbi.nlm.nih.gov/pubmed/37034124
http://dx.doi.org/10.12793/tcp.2023.31.e3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079506/
https://www.ncbi.nlm.nih.gov/pubmed/37034124
http://dx.doi.org/10.12793/tcp.2023.31.e3

Ejemplares similares